Abstract
Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.
Original language | English (US) |
---|---|
Pages (from-to) | 6369-6372 |
Number of pages | 4 |
Journal | Clinical Cancer Research |
Volume | 17 |
Issue number | 20 |
DOIs | |
State | Published - Oct 15 2011 |
ASJC Scopus subject areas
- Oncology
- Cancer Research